These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30675981)

  • 1. Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment.
    Srinivas N; Joseph SB; Robertson K; Kincer LP; Menezes P; Adamson L; Schauer AP; Blake KH; White N; Sykes C; Luciw P; Eron JJ; Forrest A; Price RW; Spudich S; Swanstrom R; Kashuba ADM
    Clin Transl Sci; 2019 May; 12(3):302-311. PubMed ID: 30675981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.
    Avery LB; Sacktor N; McArthur JC; Hendrix CW
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1409-14. PubMed ID: 23295919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
    Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
    PLoS One; 2014; 9(1):e86919. PubMed ID: 24497997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
    Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R
    Clin Pharmacokinet; 2016 Jul; 55(7):861-873. PubMed ID: 26715213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
    Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
    HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species.
    Srinivas N; Rosen EP; Gilliland WM; Kovarova M; Remling-Mulder L; De La Cruz G; White N; Adamson L; Schauer AP; Sykes C; Luciw P; Garcia JV; Akkina R; Kashuba ADM
    Xenobiotica; 2019 Oct; 49(10):1192-1201. PubMed ID: 30346892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.
    Sánchez A; Cabrera S; Santos D; Valverde MP; Fuertes A; Domínguez-Gil A; García MJ;
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5314-24. PubMed ID: 21896912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
    Best BM; Koopmans PP; Letendre SL; Capparelli EV; Rossi SS; Clifford DB; Collier AC; Gelman BB; Mbeo G; McCutchan JA; Simpson DM; Haubrich R; Ellis R; Grant I;
    J Antimicrob Chemother; 2011 Feb; 66(2):354-7. PubMed ID: 21098541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
    Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
    BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
    Avery LB; VanAusdall JL; Hendrix CW; Bumpus NN
    Drug Metab Dispos; 2013 Feb; 41(2):422-9. PubMed ID: 23166317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.
    Winston A; Amin J; Clarke A; Else L; Amara A; Owen A; Barber T; Jessen H; Avihingsanon A; Chetchotisakd P; Khoo S; Cooper DA; Emery S; Puls R; ;
    Clin Infect Dis; 2015 Apr; 60(7):1026-32. PubMed ID: 25501988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria.
    Nwogu JN; Gandhi M; Owen A; Khoo SH; Taiwo B; Olagunju A; Berzins B; Okochi H; Tallerico R; Robertson K; Babalola CP
    AIDS; 2021 Oct; 35(12):1919-1927. PubMed ID: 34115651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.
    Decloedt EH; Sinxadi PZ; van Zyl GU; Wiesner L; Khoo S; Joska JA; Haas DW; Maartens G
    J Antimicrob Chemother; 2019 Mar; 74(3):699-709. PubMed ID: 30535366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
    Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M
    J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya.
    Ngayo MO; Oluka M; Bulimo WD; Okalebo FA
    Sci Rep; 2021 Nov; 11(1):22071. PubMed ID: 34764325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
    Reay R; Dandara C; Viljoen M; Rheeders M
    OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
    Huang L; Parikh S; Rosenthal PJ; Lizak P; Marzan F; Dorsey G; Havlir D; Aweeka FT
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):310-6. PubMed ID: 22918158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
    Law JKC; Butler LT; Hamill MM
    AIDS Res Hum Retroviruses; 2020 Jun; 36(6):459-466. PubMed ID: 31931589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
    Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
    J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.